Generate QR code
Open Access
Subscription Access
Modern view on clinical phenotyping of chronic obstructive pulmonary disease
https://doi.org/10.30629/0023-2149-2024-102-7-510-517
Abstract
Chronic obstructive pulmonary disease (COPD) is a heterogeneous and multisystem disease with multiple phenotypes and a progressive increase in morbidity and mortality. This article provides a review of the current data on the identification, characterization, and features of therapy for the most common phenotypes of the disease. A literature review was conducted using medical resources such as PubMed, Google Scholar, and UpToDate, addressing issues related to phenotyping in COPD.
About the Authors
I. B. Ponomareva
Ryazan State Medical University named after Academician I.P. Pavlov of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Irina B. Ponomareva — Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Faculty Therapy named after Professor V.Y. Garmash
Ryazan
S. I. Glotov
Ryazan State Medical University named after Academician I.P. Pavlov of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Sergey I. Glotov — Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Faculty Therapy named after Professor V.Y. Garmash
Ryazan
O. M. Uryasyev
Ryazan State Medical University named after Academician I.P. Pavlov of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Oleg M. Uryasyev — Doctor of Medical Sciences, Professor, Head of the Department of Faculty Therapy named after Professor V.Y. Garmash
Ryazan
L. V. Korshunova
Ryazan State Medical University named after Academician I.P. Pavlov of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Lyudmila V. Korshunova — Candidate of Medical Sciences, Associate Professor, Associate Professor of the Department of Faculty Therapy named after Professor V.Y. Garmash
Ryazan
A. N. Ermachkova
Ryazan State Medical University named after Academician I.P. Pavlov of the Ministry of Healthcare of Russia
Russian Federation
Russian Federation
Anna N. Ermachkova — general practitioner of the State Medical Institution of the Ryazan region Polyclinic No. 12
Ryazan
References
1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2023 Report. [Electronic resource]. URL: https://goldcopd.org/2023-gold-report-2/
2. Ministry of Health of the Russian Federation [Chronic obstructive pulmonary disease: Clinical guidelines. (I n Russian)]. [Electronic resource]. URL: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdf
3. Avdeev S.N., Leshchenko I.V., Aisanov Z.R. [New concept and algorithm for the management of patients with chronic obstructive pulmonary disease. Pul’monologiya. 2023;33(5):587–594. (In Russian)]. DOI: 10.18093/0869-0189-2023-33-5-587-594
4. Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Belevskiy A.S., Leshchenko I.V., Ovcharenko S.I., Shmelev E.I. [Federal guidelines on diagnosis and treatment of bronchial asthma. Pul’monologiya. 2022;32(3):393–447. (In Russian)]. DOI: 10.18093/0869-0189-2022-32-3-393-447
5. Weatherall M., Travers J., Shirtcliff e P.M., Marsh S.E., Williams M.V., Nowitz M.R., Aldington S., Beasley R. Distinct clinical phenotypes of airways disease defi ned by cluster analysis. Eur. Respir. J. 2009;34(4):812–8. DOI: 10.1183/09031936.00174408
6. Han M.K., Agusti A., Calverley P.M. Celli B.R., Criner G., Curtis J.L., Fabbri L.M., Goldin J.G., Jones P.W., Macnee W., Make B.J., Rabe K.F., Rennard S.I., Sciurba F.C., Silverman E.K., Vestbo J., Washko G.R, Wouters E. F.M., Martinez F.J. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am. J. Respir. Crit. Care Med. 2010;182(5):598–604. DOI: 10.1164/rccm.200912-1843CC
7. Vestbo J. COPD: defi nition and phenotypes. Clin. Chest. Med. 2014;35(1):1–6. DOI: 10.1016/j.ccm.2013.10.010
8. Murakami Y., Minakata Y., Kato M., Sasaki S., Azuma Y., Kawabe K., Ono H. Determinants of Activity Phenotype in Patients With Chronic Obstructive Pulmonary Disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2023;18:1919–1929. DOI: 10.2147/COPD.S421755
9. Guerreiro I., Soccal P.M. Les phénotypes de la BPCO [COPD and phenotypes]. Rev. Med. Suisse. 2019;15(671):2082–2086. PMID: 31742938.
10. Speizer F.E., Ware J.H. Exploring diff erent phenotypes of COPD. N. Engl. J. Med. 2015;373(2):185–6. DOI: 10.1056/NEJMe1503888
11. Wu J.J., Xu H.R., Zhang Y.X., Li Y.X., Yu H.Y., Jiang L.D., Wang C.X., Han M. The characteristics of the frequent exacerbator with chronic bronchitis phenotype and non-exacerbator phenotype in patients with chronic obstructive pulmonary disease: a meta-analysis and system review. BMC Pulm. Med. 2020;20(1):103. DOI: 10.1186/s12890-020-1126-x
12. Golpe R., Suárez-Valor M., Martín-Robles I., Sanjuán-López P., Cano-Jiménez E., Castro-Añón O., de Llano L. A.P. Mortality in COPD patients according to clinical phenotypes. Int. J. Chron. Obstruct. Pulmon. Dis. 2018;13:1433–1439. DOI: 10.2147/COPD.S159834
13. Trushenko N.V., Sopova M.I., Sopova V.I. Chronic Obstructive Pulmonary Disease Phenotypes — the Way to Personaliz ed Therapy. Practical pulmonology. 2019;(3):32–39. (In Russian)].
14. Alabi F.O., Alkhateeb H.A., DeBarros K.M., Benel B.P.S., Sanchez-Martez R.L., Zeper M.L., Ismail R.A., Umeh F., Medina-Villanueva N. The heterogeneity of COPD patients in a community-based practice and the inadequacy of the global initiative for chronic obstructive lung disease criteria: a real-world experience. Chronic. Obstr. Pulm. Dis. 2021;8(3):396–407. DOI: 10.15326/jcopdf.2021.0229
15. Guerreiro I., Soccal P.M. COPD and phenotypes. Rev. Med. Suisse. 2019;15(671):2082–2086.
16. Barnes P.J. Endo-phenotyping of COPD patients. Expert Rev. Respir. Med. 2021;15(1):27–37. DOI: 10.1080/17476348.2020.1804364
17. Barnes P.J. Infl ammatory endotypes in COPD. Allergy. 2019;74(7):1249–1256. DOI: 10.1111/all.13760
18. Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., Riesco J.A., Trigueros J.A., Piñera P., Simón A., López-Campos J.L., Soriano J.B., Ancochea J. Guía Española de la EPOC (GesEPOC). Tratamiento farmacológico de la EPOC estable. Archivos de Bronconeumología, 2012;48(7),247–257. DOI: 10.1016/j.arbres.2012.04.001
19. Miravitlles M., Vogelmeier C., Roche N., Halpin D., Cardoso J., Chuchalin A.G., Kankaanranta H., Sandström T., Śliwiński P., Zatloukal J., Blasi F. A review of national guidelines for management of COPD in Europe. Eur. Respir. J. 2016;47(2):625–37. DOI: 10.1183/13993003.01170-2015
20. Lazic Z., Stankovic I., Milenkovic B., Zvezdin B., Zvezdin B., Hromis S., Jankovic S., Cupurdija V. Characteristics of COPD Phenotypes in Serbia. Int. J. Chron. Obstruct. Pulmon. Dis. 2021;16:643–654. DOI: 10.2147/COPD.S300693
21. Snider G.L. Chronic obstructive pulmonary disease: a defi nition and implications of structural determinants of airfl ow obstruction for epidemiology. Am. Rev. Respir. Dis. 1989;140(3Pt2):S3–8. DOI: 10.1164/ajrccm/140.3_Pt_2.S3
22. Yousuf A., McAuley H., Elneima O., Brightling C.E. The diff erent phenotypes of COPD. Br. Med. Bull. 2021;137(1):82–97. DOI: 10.1093/bmb/ldaa043
23. Leung J.M., Obeidat M., Sadatsafavi M., Sin D.D. Introduction to precision medicine in COPD. Eur. Respir. J. 2019;53(4):1802460. DOI: 10.1183/13993003.02460-2018
24. Miravitlles M., Soler-Cataluña J.J., Calle M., Soriano J.B. Treatment of COPD by clinical phenotypes: putting old evidence into clinical practice. Eur. Respir. J. 2013;41(6):1252–6. DOI: 10.1183/09031936.00118912
25. Siafakas N., Corlateanu A., Fouka E. Phenotyping Before Starting Treatment in COPD? COPD. 2017;14(3):367–374. DOI: 10.1080/15412555.2017.1303041
26. Garcia-Aymerich J., Gómez F.P., Benet M., Farrero E., Basagaña X., Gayete À., Paré C., Freixa X., Ferrer J., Ferrer A., Roca J., Gáldiz J.B., Sauleda J., Monsó E., Gea J., Barberà J.A., Agustí À., Antó J.M. Identifi cation and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–7. DOI: 10.1136/thx.2010.154484
27. Rizzi A., Amari G., Pivetti F., Delcanale M., Amadei F., Pappani A., Fornasari L., Villetti G., Marchini G., Pisano A.R., Pitozzi V., Pittelli M.G., Trevisani M., Salvadori M., Cenacchi V., Fioni A., Puccini P., Civelli M., Patacchini R., Baker-Glenn C., Van de Poël H., Blackaby W., Nash K., Armani E. Optimization of M3 Antagonist-PDE4 Inhibitor (MAPI) Dual Pharmacology Molecules for the Treatment of COPD. J. Med. Chem. 2023;66(16):11476–11497. DOI: 10.1021/acs.jmedchem.3c01012
28. Cazzola M., Calzetta L., Page C., Jardim J., Chuchalin A.G., Rogliani P., Matera M.G. Infl uence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev. 2015;24(137):451–461. DOI: 10.1183/16000617.00002215
29. Poole P., Black P.N., Cates C.J. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012;(8):CD001287. DOI: 10.1002/14651858.cd001287. pub4
30. Zeng Z., Yang D., Huang X., Xiao Z. Eff ect of carbocisteine on patients with COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017;12:2277–2283. DOI: 10.2147/COPD.S140603
31. Dal Negro R., Wedzicha J., Iversen M. Fontana G., Page C., Cicero A.F., Pozzi E., Calverley P. M.A. Eff ect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017;50(4):1700711. DOI: 10.1183/13993003.00711-2017
32. Donath E., Chaudhry A., Hernandez-Aya L.F., Lit L. A meta-analysis on the prophylactic use of macrolide antibiotics for the prevention of disease exacerbations in patients with Chronic Obstructive Pulmo- nary Disease. Respir. Med. 2013;107(9):1385–1392. DOI: 10.1016/j.rmed.2013.05.004
33. Albert R.K., Connett J., Bailey W.C., Richard Casaburi, Cooper J.A.D., Criner G.J., Curtis J.L., Dransfi eld M.T., Han M.K., Lazarus S.C., Make B., Marchetti N., Martinez F.J., Madinger N.E., McEvoy C., Niewoehner D.E., Porsasz J., Price C.S., Reilly J., Scanlon P.D., Sciurba F.C., Scharf S.M., Washko G.R., Woodruff P.G., Anthonisen N. R. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011;365(8):689–698. DOI: 10.1056/nejmoa1104623
34. Suissa S., Ernst P. Observational studies of inhaled corticosteroid effectiveness in COPD: lessons learned. Chest. 2018;154(2):257–265. DOI: 10.1016/j.chest.2018.04.006
35. Kendzerska T., Aaron S.D., To T., Licskai C., Stanbrook M., Vozoris N.T., Hogan M.E., Tan W.C., Bourbeau J., Gershon A.S. Eff ectiveness and safety of inhaled corticosteroids in older individuals with chronic obstructive pulmonary disease and/or asthma. A population study. Ann. Am. Thorac. Soc. 2019;16(10):1252–1262. DOI: 10.1513/AnnalsATS.201902-126OC
36. White P., Thorntoh H., Pinnock H., Georgopoulou S., Booth H.P. Overtreatment of COPD with inhaled corticosteroids – implications for safety and costs: cross-sectional observational study. PLoS One. 2013;8(10):e75221. DOI: 10.1371/journal.pone.0075221
37. Somayaji R., Chalmers J.D. Just breathe: a review of sex and gender in chronic lung disease. Eur. Respir. Rev. 2022;31(163):210111. DOI: 10.1183/16000617.0111-2021
38. Nikolaou V., Massaro S., Fakhimi M., Stergioulas L., Price D. COPD phenotypes and machine learning cluster analysis: a systematic review and future research agenda. Respir. Med. 2020;171:106093. DOI: 10.1016/j.rmed.2020.106093
39. Ghebre M.A., Pang P.H., Diver S., Desai D., Bafadhel M., Haldar K., Kebadze T., Cohen S., Newbold P., Rapley L., Woods J., Rugman P., Pavord I.D., Johnston S.L., Barer M., May R.D., Brightling C.E. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profi les. J. Allergy Clin. Immunol. 2018;141(6):2027–2036.e12. DOI: 10.1016/j.jaci.2018.04.013
40. Ovcharenko S.I. Phenotypes of chronic obstructive pulmonary disease and the ECLIPSE study: preliminary results. Pul’monologiya. 2011;3:113–117.(In Russian)].
41. Vestbo J., Anderson W., Coxson H.O., Crim C., Dawber F., Edwards L., Hagan G., Knobil K., Lomas D.A., MacNee W., Silverman E.K., Tal-Singer R. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoint (ECLIPSE). Eur. Respir. J. 2008;31:869–873. DOI: 10.1183/09031936.00111707
42. Hurst J.R., Vestbo J., Anzueto A., Locantore N., Müllerova H., Tal-Singer R., Miller B., Lomas D.A., Agusti A., Macnee W., Calverley P., Rennard S., Wouters E.F. M., Wedzicha J.A. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010;363:1128–1138. DOI: 10.1056/NEJMoa0909883
43. Han M.K., Kazerooni E.A., Lynch D.A., Liu L.X., Murray S., Curtis J.L., Criner G.J., Kim V., Bowler R.P., Hanania N.A., Anzue to A.R., Make B. J., Hokanson J.E., Crapo J.D., Silverman E.K., Martinez F.J., Washko G.R. Chronic Obstructive Pulmonary Disease Exacerbations in the COPDGene Study: Associated Radiologic Phenotypes. Radiology. 2011;261(1):274–82. DOI: 10.1148/radiol.11110173
44. Nishimura M., Makita H., Nagai K., Konno S., Nasuhara Y., Hasegawa M., Shimizu K., Betsuyaku T., Ito Y.M., Fuke S., Igarashi T., Akiyama Y., Ogura S. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(1):44–52. DOI: 0.1164/rccm.201106-0992OC
45. Kume H., Hojo M., Hashimoto N. Eosinophil Infl ammation and Hyperresponsiveness in the Airways as Phenotypes of COPD, and Usefulness of Inhaled Glucocorticosteroids. Front Pharmacol. 2019;25:10:765. DOI: 10.3389/fphar.2019.00765
46. Huang W.C., Tsai Y.H., Wei Y.F., Kuo P.H., Tao C.W., Cheng S.L., Lee C.H., Wu Y.K., Chen N.H., Hsu W.H., Hsu J.Y., Wang C.C., Lin M.S. Wheezing, a signifi cant clinical phenotype of COPD: experience from the Taiwan Obstructive Lung Disease Study. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:2121–2126. [Electronic resource]. URL: https://www.semanticscholar.org/reader/4a7b7f49b-0caeba6195bd3566568f60157cd030a
47. González-García M., Torres-Duque C. Wood smoke COPD: a new description of a COPD phenotype? Eur. Respir. J. 2014;44(1):261–2. DOI: 10.1183/09031936.00222913
48. Torres-Duque C.A., García-Rodriguez M.C., González-García M. Is chronic obstructive pulmonary disease caused by wood smoke a diff erent phenotype or a diff erent entity? Arch. Bronconeumol. 2016;52(8):425–31. DOI: 10.1016/j.arbres.2016.04.004
49. Ji W., Lim M.N., Bak S.H., Hong S.H., Han S.S., Lee S.J., Kim W.J., Hong Y. Diff erences in chronic obstructive pulmonary disease phenotypes between non-smokers and smokers. Clin. Respir. J. 2018;12(2):66–67. DOI: 10.1111/crj.12577
50. Perret J.L, Abramson M.J. Biomass smoke COPD: A phenotype or a diff erent disease? Respirology. 2018;23(2):124–125. DOI: 10.1111/resp.13227
51. Ovsyannikov E.S., Budnevsky A.V., Shkatova Ya.S. Evaluation of respiratory muscle training eff ectiveness in patients with chronic obstructive pulmonary disease and obesity. I.P. Pavlov Russian Medical Biological Herald. 2019;27(3):367–74. (In Russian)]. DOI: 10.23888/PAVLOVJ2019273367-374.
52. Kotlyarov S.N., Motynga K.A. Physical weakness as COPD phenotype. Science of the young (Eruditio Juvenium). 2020;8(4):599–608. (In Russian)]. DOI: 10.23888/HMJ202084599-608
53. Abrosimov V.N., Peregudova N.N., Kosyakov A.V. Evaluation of functional parameters of respiratory system in patients with chronic obstructive pulmonary disease in 6-minute walking test. Science of the young (Eruditio Juvenium). 2019;7(3):323–31. (In Russian)]. DOI: 10.23888/HMJ201973323-331
54. Mesquita R., Spina G., Pitta F., Donaire-Gonzalez D., Deering B.M., Patel M.S. , Mitchell K.E., Alison J., van Gestel A.J., Zogg S., Gagnon Ph., Abascal-Bolado B., Vagaggini B., Garcia-Ayme rich J., Jenkins S.C., Romme E.A., Kon S. S., Albert P.S., Waschki B., Shrikrishna D., Singh S.J., Hopkinson N.S., Miedinger D., Benzo R.P., Maltais F., Paggiaro P., McKeough Z.J., Polkey M.I., Hill K., Man W.D-C., Clarenbach C. F., Hernandes N.A., Savi D., Wootton S., Furlanetto K.C., Cindy Ng L.W., Vaes A.W., Jenkins C., Eastwood P.R., Jarreta D., Kirsten A., Brooks D., Hillman D.R., Sant’Anna T., Meijer K., Dürr S., Rutten E.P., Kohler M., Probst V.S., Tal-Singer R., Gil E.G., den Brinker A.C., Leuppi J.D., Calverley P.M., Smeenk F.W., Costello R.W., Gramm M., Goldstein R., Groenen M.T., Magnussen H., Wouters, E.F., ZuWallack R.L., Amft O., Watz H., Spruit M. A. Physi cal activity patterns and clusters in 1001 patients with COPD. Chron. Respir. Dis. 2017;14(3):256–269. DOI: 10.1177/1479972316687207
55. Vogiatzis I., Nanas S., Roussos C. Interval training as an alternative modality to continuous exercise in patients with COPD. Eur. Respir. J. 2002;20:12–19. DOI: 10.1183/09031936.02.01152001
56. Sillen M.J., Franssen F.M., Delbressine J.M., Vaes A.W., Wouters E.F.M., Spruit M.A. Effi cacy of lower-limb muscle training modalities in severely dyspnoeic individuals with COPD and Mesquita et al. 13 quadriceps muscle weakness: results from the DICES trial. Thorax. 2014;69:525–531. DOI: 10.1136/thoraxjnl-2013-204388
57. Camillo C.A., Burtin C., Hornikx M., Demeyer H., De Bent K., van Remoortel H., Osadnik C.R., Janssens W., Troosters T. Physiological responses during downhill walking: A new exercise modality for subjects with chronic obstructive pulmonary disease? Chron. Respir. Dis. 2015;12:155–164. DOI: 10.1177/147997231557571
58. Spruit M.A., Augustin I.M.L., Vanfl eteren L.E., Janssen D.J.A., Gaff ron S., Pennings H.-J., Smeenk F., Pieters W., van den Bergh J.J.A.M., Michels A.-J., Groenen M.T.J., Rutten E.P.A., Wouters E.F.M., Franssen F.M.E. Diff erential response to pulmonary rehabilitation in COPD: multidimensional profi ling. Eur. Respir. J. 2015;46:1625–1635. DOI: 10.1183/13993003.00350-2015
59. Donaire-Gonzalez D., Gimeno-antos E., Balcells E., de Batlle J., Ramon M.A., Rodriguez E., Farrero E., Benet M., Guerra S., Sauleda J., Ferrer A., Ferrer J., Barberà J.A., Rodriguez-Roisin R., Gea J., Agustí A., Antó J.M., Garcia-Aymerich J. Benefi ts of physical activity on COPD hospitalisation depend on intensity. Eur. Respir. J. 2015;46:1281–1289. DOI: 10.1183/13993003.01699-2014
60. Chan S.M.H., Selemidis S., Bozinovski S., Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in Chronic Obstructive Pulmonary Disease (COPD): clinical signifi cance and therapeutic strategies. Pharmacol. Ther. 2019;198:160–88. DOI: 10.1016/j.pharmthera.2019.02.013
61. Sepúlveda-Loyola W., Osadnik C., Phu S., Morita A.A., Duque G., Probst V.S. Diagnosis, prevalence, and clinical impact of Sarcopenia in COPD: a systematic review and meta-analysis. J. Cachexia Sarcopenia Muscle. 2020;11(5):1164–76. DOI: 10.1002/jcsm.12600
62. Sayer A.A., Cruz-Jentoft A. Sarcopenia defi nition, diagnosis and treatment: consensus is growing. Age Ageing. 2022;51(10):afac220. DOI: 10.1093/ageing/afac220
63. Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyère O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., Schneider S.M., Sieber C.C., Topinkova E., Vandewoude M., Visser M., Zamboni M. Sarcopenia: revised European consensus on defi nition and diagnosis. Age Ageing. 2019;48(1):16–31. DOI: 10.1093/ageing/afy169
64. Wang Z., Zhou X., Deng M., Yin Y., Li Y., Zhang Q., Bian Y., Miao J., Li J., Hou G. Clinical Impacts of Sarcopenic Obesity On Chro nic Obstructive Pulmonary Disease: a Cross-sectional Study. BMC Pulm. Med. 2023;23(1):394. DOI: 10.1186/s12890-023-02702-2
65. Sanchez-Rodriguez D., Marco E, Cruz-Jentoft A.J. Defi ning sarcopenia: some caveats and challenges. Curr. Opin. Clin. Nutr. Metab. Care. 2020;23:127–32. DOI: 10.1097/MCO.0000000000000621
66. Wu Z., Yang D., Ge Z., Yan M., Wu N., Liu Y. Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: a retrospective real world research. J. Thorac. Dis. 2018;10(8):5086–5099. DOI: 10.21037/jtd.2018.08.67
67. Chan S.M.H., Selemidis S., Bozinovski S., Vlahos R. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical signifi cance and therapeutic strategies. Pharmacol. Ther. 2019;198:160–188. DOI: 10.1016/j.pharmthera.2019.02.013
68. Uchida A., Sakaue K., Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol. Int. 2018;67(2):165–171. DOI: 10.1016/j.alit.2018.02.002.
69. Milne S., Mannino D., Sin D.D. Asthma-COPD overlap and chronic airfl ow obstruction: defi nitions, management, and unanswered questions. J. Allergy Clin. Immunol. Prac. 2020;8(2):483–495. DOI: 10.1016/j.jaip.2019.10.044
70. Pahus L., Burgel P.R., Roche N., Paillasseur J.L., Chanez P. Randomized controlled trials of pharmacological treatments to prevent COPD exacerbations: applicability to real-life patients. BMC Pulm. Med. 2019;19(1):127. DOI: 10.1186/s12890-019-0882-y
71. Carolan B.J., Sutherland E.R. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: Recent advances. J. Allergy Clin. Immunol. 2013;131(3):627–34; quiz 635. DOI: 10.1016/j.jaci.2013.01.010
72. Fingleton J., Huang K., Weatherall M., Guo Y., Ivanov S., Bruijnzeel P., Zhang H., Wang W., Beasley R., Wang C. Phenotypes of symptomatic airways disease in China and New Zealand. Eur. Respir. J. 2017;50(6):1700957. DOI: 10.1183/13993003.00957-2017.S
73. Reddel H.K., de Verdier M.G., Agustí A., Anderson G., Beasley R., Bel E.H., Janson C., Make B., Martin R.J., Pavord I., Price D., Keen C., Gardev A., Rennard S., Sveréus A., Bansal A.T., Brannman L., Karlsson N., Nuevo J., Nyberg F., Young S.S., Vestbo J. Prospective observational study in patients with obstructive lung disease: NOVELTY design. ERJ Open Res. 2019;5(1):00036–2018. DOI: 10.1183/23120541.00036-2018
74. Reddel H.K., Vestbo J., Agustí A., Anderson G.P., Bansal A.T., Beasley R., Bel E.H., Janson C., Make B., Pavord I.D., Price D., Rapsomaniki E., Karlsson N., Finch D.K., Nuevo J., de Giorgio-Miller A., Alacqua M., Hughes R., Müllerová H., de Verdier M.G. Heterogeneity within and between physician-diagnosed asthma and/ or COPD: NOVELTY cohort. Eur. Respir. J. 2021;58(3):2003927. DOI: 10.1183/13993003.03927-2020
75. Hughes R., Rapsomaniki E., Janson C., Keen C., Make B.J., Burgel P.R., Tomaszewski E.L., Müllerová H., Reddel H.K. Frequent productive cough: symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study. Respir. Med. 2022;200:106921. DOI: 10.1016/j.rmed.2022.106921
76. Agustí A., Rapsomaniki E., Beasley R., Hughes R., Müllerová H., Papi A., Pavord I.D., van den Berge M., Faner R. Treatable traits in the NOVELTY study. Respirology. 2022;27(11):929–940. DOI: 10.1111/resp.14325
77. Hughes R., Rapsomaniki E., Bansal A.T., Vestbo J., Price D., Agustí A., Beasley R., Fageras M., Alacqua M., Papi A., Müllerová H., Reddel H.K. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum. J. Allergy Clin. Immunol. Pract. 2023;11(9):2803–2811. DOI: 10.1016/j.jaip.2023.05.013
78. David B., Bafadhel M., Koenderman L., De Soyza A. Eosinophilic infl ammation in COPD: from an infl ammatory marker to a treatable trait. Thorax. 2021;76(2):188–195. DOI: 10.1136/thoraxjnl-2020-215167
79. Papaporfyriou A., Bakakos P., Hillas G., Papaioannou A.I., Loukides S. Blood eosinophils in COPD: friend or foe? Expert Rev. Respir. Med. 2022;16(1):35–41. DOI: 10.1080/17476348.2021.2011219
80. Kang H.S., Kim SK., Kim YH, Kim J.W., Lee S.H., Yoon H.K., Rhee C.K. The association between eosinophilic exacerbation and eosinophilic levels in stable COPD. BMC Pulm. Med. 2021;21(1):74. DOI: 10.1186/s12890-021-01443-4
81. Segal L.N., Martinez F.J. Chronic obstructive pulmonary disease subpopulations and phenotyping. J. Allergy Clin. Immunol. 2018;141(6):1961–1971. DOI: 10.1016/j.jaci.2018.02.035
82. Uwagboe I., Adcock I.M., Bello F.L., Caramori G., Mumby S. New drugs under development for COPD. Minerva Med. 2022;113(3):471– 496. DOI: 10.23736/S0026-4806.22.08024-7
83. Trinkmann F., Schaefer J., Gawlitza J., Drayss J., Schroeter M., Michels J.D., Akin I., Borggrefe M., Saur J. COPD phenotyping and diff erential therapy can be improved using impulse oscillometry and multiple breath washout testing. American journal of respiratory and critical care medicine. 2019;199(9). DOI: 10.1164/ajrccm-conference.2019.199.1_MeetingAbstracts.A2409
Review
For citations:
Ponomareva I.B., Glotov S.I., Uryasyev O.M., Korshunova L.V., Ermachkova A.N. Modern view on clinical phenotyping of chronic obstructive pulmonary disease. Clinical Medicine (Russian Journal). 2024;102(7):510–517. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-7-510-517
Views:
258
Email this article 